cyrilzakka/clinical-trials huggingface dataset:
CPAP vs AutoCPAP for Treatment of Obstructive Sleep Apnea (OSA) in the Postoperative Setting

The purpose of this study is to determine if an Autoadjusting CPAP machine is better than the regular CPAP machine in treatment of Obstructive Sleep Apnea in the postoperative setting.

The purpose of this study is to determine if an Autoadjusting CPAP machine is better than the regular CPAP machine in treatment of Obstructive Sleep Apnea in the postoperative setting.

Patients with known Obstructive Sleep Apnea who are on CPAP therapy at home and undergo an elective surgery (meeting specified inclusion and exclusion criteria) will be randomized to either using Autoadjusting CPAP vs their usual CPAP at their prescribed settings the night after surgery. During that night, they will be monitored with full polysomnography in their hospital bed.

Eligibility Criteria:
Inclusion Criteria:

1. Known OSA patients well-controlled by CPAP (not hypoxemic i.e. Oxygen Saturation (SaO2) ≥ 89% and post-treatment Apnea Hypopnea (AHI) \<10) and compliant ( \> 3 hours per night) presenting for elective inpatient surgery to MetroHealth Medical Center
2. Elective extremity or lower abdominal surgery
3. Age \>18 years

Exclusion Criteria:

1. Surgery that may cause hypoxemia from causes other than the effect on upper airway patency e.g. any thoracic surgery, upper abdominal surgery, head and neck surgery.
2. Surgery on the upper-airway.
3. Any condition that may interfere with application of CPAP mask e.g. trauma, surgery on the face, vomiting, naso-gastric intubation etc.
4. OSA treated with a device other than CPAP e.g. Bilevel positive pressure or V-Positive Airway Pressure
5. OSA needing very high levels of CPAP i.e. \> 16 cms to achieve adequate control
6. OSA or other underlying cardiopulmonary conditions that require supplemental oxygen
7. Patients with decompensated congestive heart failure or advanced Chronic Obstructive Pulmonary Disease (COPD) (FEV1\<35% of predicted)
8. Patients with neuromuscular impairment
9. Patients with central sleep apnea
10. Pregnant patients
11. Decisional impaired subjects who are not able to consent
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer


Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years of age
* Patients with prostate cancer that is recurrent or did not respond to previous hormone therapy and/or who have exhausted standard treatment options.

For the dose escalation parts only:

Patients who have exhausted standard treatment options with recurrent or refractory cancer (ovarian cancer, cervical squamous cell carcinoma, breast cancer, salivary gland cancer, endometrial cancer)

* Histologically or cytologically documented diagnosis of cancer
* Measurable disease according to RECIST Version 1.1 or for prostate cancer also evaluable disease according to Prostate Cancer Working Group 2 (PCWG2) eligibility criteria or for ovarian cancer also evaluable disease (non-measurable) according to Gynaecologic Cancer Intergroup (GCIG) criteria
* Absolute neutrophil count ≥1.5 (1500/mm3) and platelets ≥100 × 109/L (without platelet transfusion within the last 4 weeks before first study drug administration), and haemoglobin ≥9 g/dL at Screening
* Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal (ULN), Total bilirubin ≤1.5 × ULN (exception: patients with liver metastasis are allowed to have aspartate aminotransferase ≤5 × ULN and alanine aminotransferase ≤5 × ULN) at screening
* Albumin ≥26 g/L at Screening

Exclusion Criteria:

* Concurrent prior treatment-related toxicity of Grade 2 or higher. Exception: any toxicity that is in the view of the investigator not a clinically significant safety risk for Investigational medicinal product (IMP) administration.
* Previous treatment with cytotoxic chemotherapy or other anticancer therapy within 4 weeks before the first dosing with study drug (at least 6 weeks for mitoxantrone, nitrosurea, and bicalutamide).
* Treatment with systemic glucocorticosteroids of more than a 2 mg dexamethasone equivalent per day or in cases of treatment with ≤2 mg dexamethasone equivalent per day:

  1. Dosing was changed within 6 weeks before Screening or
  2. The patient's cancer is responding to glucocorticosteroid intake
* Radiation therapy within 4 weeks prior to the first dosing with IMP.
* Treatment with a systemic IMP in a clinical trial within 28 days before the Screening Visit.
* Current or past history of clinically significant gastrointestinal disease or major gastrointestinal surgery, malabsorption syndrome, or other conditions that could interfere with enteral absorption.
* Concurrent clinically significant unrelated systemic illness (e.g., serious infection) or significant pulmonary, hepatic, or other organ dysfunction that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.
Assessing the Feasibility and Acceptability of a Social Identity Informed Virtual Running Group Program

The STRIDE Pilot Trial is a randomized controlled pilot trial that will utilize social identity informed virtual running groups to support underactive undergraduate students' well-being and exercise behaviour. The main outcomes of this study are to determine whether the intervention is feasible and acceptable to conduct as a full-scale efficacy trial. Secondary outcomes of interest include changes in participants' exercise identity, exercise behaviour, perceived social support, and well-being. Participants' perceived social identification with their running group will also be assessed at the end of the study.


Eligibility Criteria:
Inclusion Criteria:

* currently residing in Canada
* age 18+
* enrolled in undergraduate studies at the University of British Columbia
* underactive (i.e., currently participating in less than the Canadian physical activity guidelines of 150 minutes of physical activity per week)
* not experience any health contraindication which might prevent that person from participating in moderate-to-vigorous intensity exercise.
* able to speak and read English
* own a smart phone
* have home access to the internet and a device with camera functionality

Exclusion Criteria:

* If a potential participant has a medical contraindication (flagged through the PAR-Q+ and ePARmedX) and have NOT been cleared to participate in physical activity by their physician they are then ineligible to participate in the study
* Participants are asked to record their running and walking behaviour on the fitness application Strava, and participate in Zoom coffee chats with their running group. If an individual is unwilling to download the Strava application and/or do not want to use Zoom they will be excluded from the study.
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

The study goal is to compare surgeon-palliative care team co-management, versus surgeon alone management, of patients and family members preparing for major upper gastrointestinal cancer surgery. The study also aims to explore, using qualitative methods, the impact of surgeon-palliative care team co-management versus surgeon alone management on the perioperative care experience for patients, family members, surgeons, and palliative care clinicians.

The components of surgeon palliative care team co management practices will include Time, Education, Assessments, and Multi disciplinary (TEAM) element.

1. Time; At least 60 minutes/month (per patient and caregiver preference) devoted to palliative care treatments for the patient and family
2. Education - Patients and family members, per their desires and wishes, are counseled and educated about their disease, including self-management of symptoms, prognosis, and treatment options
3. Assessment - Formal assessment of symptoms including pain, dyspnea, constipation/diarrhea, anxiety/depression, fatigue, and nausea. Edmonton symptom score33 will be used as a formal assessment.
4. Multi-Disciplinary - Management must be multi disciplinary with access to a multi-disciplinary palliative care team composed of nurse, physician, social worker, pharmacist, and/or chaplain team members.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age and must be able to give informed consent.
* Diagnosed with pancreatic cancer or hepatocellular cancer or esophageal cancer or gastric cancer and/or cholangio carcinomas
* Non emergent, upper gastrointestinal cancer related surgery with a goal of primary resection of the tumor- optimal surgical goal is cure, not merely disease palliation.
* One companion per patient will be allowed to participate. In addition, to being identified by the patient at being a key caregiver throughout the surgery period, these companions must be able to give informed consent and at least 18 years of age.

Exclusion Criteria:

* No previous involvement of palliative care providers in their care course
Robot-assisted Gait Training in Multiple Sclerosis Subjects

Aims of the study:

This is a randomized-controlled trial to test the effects of robot-assisted gait training on locomotor function and motor unit firing rate in multiple sclerosis subjects with severe gait impairments. The control group will be treat with conventional physical therapy.

Subjects and methods:

60 multiple sclerosis patients will be recruited in two outpatient rehabilitation clinics.

Informed consent will be obtained. Participants will be randomized to Robot-assisted gait training (experimental group) or conventional therapy (control group) through a randomization stratification approach, according to a block randomization of 4.

The experimental group will receive 12 robot-assisted gait training sessions over 6 weeks (2 sessions/week). The control group will receive 12 conventional therapy sessions over 6 weeks (2 sessions/week), that will focus on gait training.

Primary outcome measures will be both neurophysiological measures (motor unit firing rate characteristics) and clinical test for gait speed (10m walking test). Secondary outcome measures will include: clinical tests of walking endurance (six minute walking test), balance (Berg Balance Test) and mobility (Up and Go Test).

Clinical assessment of lower-extremities spasticity (Modified Ashworth Scale), motor fatigue (Fatigue Severity Scale), depression (PHQ-9) and quality of life (SF-36) will be monitored. Subject acceptance and confidence in the treatments will be track with a Visual Analog Scale. Outcome measures will be assessed the week prior to treatment initiation (T0), after 6 sessions (T1), the week after the end of treatment (T2) and at 3 months follow-up (T3) to evaluate treatments retention, by a clinician blinded to the treatment.


Eligibility Criteria:
Inclusion Criteria:

* males and females, community dwelling, age 18 or older
* diagnosis of multiple sclerosis in a stable phase, with relapses \> 6 months prior to study enrollment
* moderate to severe gait impairments referred to Expanded Disability Status Scale (EDSS) between 6 and 7

Exclusion Criteria:

* neurologic conditions in addition to multiple sclerosis that may affect motor function
* medical conditions likely to interfere with the ability to safely complete the study
* impaired cognitive functioning: Mini Mental Status Examination \< 24
* severe lower-extremities spasticity or contractures that may limit range of motion(Ashworth score \>4 for hip, knee or ankle flexors/extensors
Relationship Between Children's Colour Preferences and Their Dental Anxiety

The objective of this study was to examine the relationship between children's color preferences and their dental anxiety. It aims to answer are:

1. Is there a relationship between children's compomer restoration colour preferences and dental anxiety?
2. Do children's compomer restoration colour preferences vary according to age and gender?
3. Are children's compomer restoration colour preferences the same as their favourite colours?

Background: Dental fear and anxiety, which are frequently encountered in children, are recognised as an important public health problem in many countries and this situation leads to postponement and neglect of dental treatments. The aim of this study is to evaluate the relationship between colored compomer color preferences and dental anxiety levels, which are frequently used in the restorative treatments of pediatric patients who need restorative treatment of primary molar teeth.

Methods: In this study, the relationship between anxiety levels and compomer restoration color preferences was evaluated in 275 patients aged between 5 and 10 years who required restorative treatment in primary molar teeth. Children's dental anxiety levels were determined using the Modified Child Dental Anxiety Scale, face version (MCDAS-f). Children with identified anxiety levels were asked to choose colors for their fillings. A scale consisting of 9 colors (pink, blue, gold, silver, orange, yellow, green, purple, white) was used for color selection by adding white to the colored compomer scale.

Eligibility Criteria:
Inclusion Criteria:

* the child must be between 5-10 years old
* who needed restorative treatment of their deciduous molars
* no systemic disease or syndrome

Exclusion Criteria:

* the child is under 5 years old and over 10 years old
* who not needed restorative treatment of deciduous molars and haven't those teeth
* having any systemic disease or syndrome
PF-00489791 For The Treatment Of Raynaud's

The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.


Eligibility Criteria:
Inclusion Criteria:

* Active Raynaud's Phenomenon
* Stable disease and medication requirements over the previous two months
* For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome
* both sexes

Exclusion Criteria:

* Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates
* Smoking within 3 months or smoking cessation using nicotine products
* Subjects currently taking sildenafil, tadalafil or vardenafil
* Subjects with ulnar arterial occlusive disease as shown by a modified Allen test
* Pregnant or breast feeding or considering pregnancy in next 4 months
* Participation in trial for investigational drug within 30 days
Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

A real world evidence study that aims to understand the impact of RYALTRIS® nasal spray in patients with Allergic Rhinitis over a 28-day period.

The aim of this research is to develop a greater understanding of satisfaction with RYALTRIS® nasal spray in patients with Allergic Rhinitis (AR). There is currently no real-world evidence for patient satisfaction data with RYALTRIS® nasal spray. To address this knowledge gap and add to clinically relevant data to support Quality of Life (QoL) and patient reported outcomes, this research will evaluate the impact on quality of life (symptom control), using a Visual Analogue Scale (VAS), following initiation of RYALTRIS® to explore the relationship between baseline and subsequent QoL scores among patients initiated on RYALTRIS®.

Eligibility Criteria:
Inclusion Criteria:

AR patients (moderate-to-severe SAR or PAR) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:

* Patients above 18 years old
* Fluent in English
* Patients newly prescribed RYALTRIS® who have not yet initiated treatment
* Willing and able to provide consent to participate

Exclusion Criteria:

Potential participants will be excluded if they:

* Are employed by a pharmaceutical company (to avoid conflict of interest)
* Are employed by a vaccine company (to avoid conflict of interest)
* Do not have access to the internet (to ensure validity of the data)
* Are unable to read and understand English (to ensure validity of the data)
* are currently or have previously been on RYALTRIS®
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.


Eligibility Criteria:
Inclusion Criteria:

* Adults of any age ≥ 18
* Men and non-pregnant, non-lactating women
* Women of childbearing potential had a negative serum (Beta HCG) pre-study pregnancy test prior to randomization
* Women of childbearing potential used an acceptable form of contraception
* Patients with a clinical diagnosis of idiopathic Parkinson's Disease, i.e., not induced by drugs or caused by other diseases;
* Patients classified as stage (II-IV) of the Hoehn and Yahr scale for staging the severity of Parkinson's Disease
* The patient must have been on an optimally maximized oral therapy regimen. Optimized oral anti-parkinson medications must have included levodopa/carbidopa inhibitors, in either immediate or delayed release forms, plus at least one direct acting oral dopamine agonist for at least 30 days prior to randomization
* Patients must have been receiving apomorphine subcutaneous injections for rescue therapy for Off events for at least three months
* The minimum apomorphine baseline-dosing requirement was an average of at least 2 doses per day over the week prior to enrollment.
* Patients participating in protocol APO401, an open-label study primarily designed to collect safety data, were eligible for participation in this trial without termination of participation in APO401

Exclusion Criteria:

* Patients under medical therapy for clinically significant psychoses or dementia not related to ingestion of anti-parkinson medications. (Patients with hallucinations or other central adverse reactions associated solely with anti-parkinson medications were not excluded.)
* Patients with a history of drug or alcohol dependency within one year prior to study enrollment
* Patients with unstable and clinically significant disease of cardiovascular (including orthostatic hypotension), hematologic (including Coombs' positive hemolytic anemia), hepatic, renal, metabolic, respiratory, gastrointestinal or endocrinological systems or neoplasm within the three months before the start of the study.
* Patinets with a history of true allergy to morphine or its derivatives (including apomorphine), sulfur, sulfur containing medications, sulfites, sulfates, Tigan(R)(trimethobenzamide).
* Patients treated with experimental agents (other than apomorphine intermittent subcutaneous injections) within 30 days before study entry. Patients with participation in MYLAN-sponsored study APO202 were excluded from participation in this study.
* Patients whose apomorphine regimen was characterized by administration methods other than intermittent subcutaneous injection.
* Patients who could not or would not sign an Informed Consent form.
Evaluation of Lactobacillus Fermentum CECT5716 on the Incidence of Mastitis

To evaluate the effect of the consumption of Lactobacillus fermentum CECT5716 on mastitis incidence.

Previous studies have demonstrated that L. fermentum CECT5716, a probiotic strain previously isolated from breast milk, can be used as an effective treatment of mastitis and painful breastfeeding by reducing pathogen counts in breast milk. This is a randomized double blinded controlled study to evaluate the effect of L.fermentum CECT5716 on mastitis incidence and Staphylococcus load in breast milk. Women will be recruited 1-6 days after child birth and distributed into two groups: Probiotic group receiving 1 capsule/day containing L.fermentum 3x109cfu; Control group receiving 1 placebo capsule/day containing maltodextrin. The intervention period is 16 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Healthy women between 18 and 40 years with development of normal pregnancy Birth between 37 and 42 weeks of gestation. Women who have received antibiotic treatment between 48 hours before and 48 hours after childbirth (one dose is sufficient for inclusion regardless of the type of antibiotic).

Childbirth took place 1-7 days prior to recruitment.. With firm intention to breast-feed their children for at least 16 weeks..

Exclusion Criteria:

* - Mammary pathologies that hinder or preclude breastfeeding.
* Low expectation of adherence to the study protocol.
Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation.

The purpose of this study is to investigate whether revalidation following total hip replacement through the percutaneous approach is faster or better than following the anterolateral approach. We assume this would be the case since it is possible to spare a large part of the gluteus medius muscle with the percutaneous approach.


Eligibility Criteria:
Inclusion Criteria:

* unilateral hip arthritis or avascular necrosis (AVN) in need for total hip replacement

Exclusion Criteria:

* Comorbidities affecting functional outcome
* Symptomatic lumbar pathology
* Need of surgery or intervention on the ipsilateral knee and/or ankle/foot
* Neurological disorders such as Parkinsonism and previous cardiovascular accidents (CVA)
Effectiveness of PEMF in Patients With Chronic Radicular Pain Due to Lomber Disc Herniation

The aim of this study is to investigate the effectiveness of pulse magnetic field therapy on pain, functional status, and quality of life in patients with chronic radicular pain due to lumbar disc herniation.

Pulsed Electromagnetic Field Therapy (PEMF) is a non-invasive, painless treatment for various injuries, bone related conditions and pains. However, further studies on PEMF effects on low back and radicular pain is needed due to lack of studies in this area.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-65
* Unilateral radicular pain for at least 3 months
* Severity of radicular pain with Visual Analog Score of at least 4/10
* Written informed consent

Exclusion Criteria:

* Pregnancy or lactation
* Cardiac pacemaker, or any metal implants or electronic devices anywhere in the body
* History of surgery or algological procedure of the lumbar region
* Physical therapy within the last year due to back pain
* Previous PEMF treatment
* Malignancy or suspicion
* Polyneuropathy (diabetic or other)
* Connective tissue disease
* Presence of inflammatory joint pain
* Fibromyalgia
* Presence of open surface wound
* Tuberculosis, mycosis, or viral disease
* Presence of pain in another region of the body with higher severity than radicular back pain
* Use of drugs other than paracetamol-derivative simple analgesics (Nonsteroidal Aanti inflammatuar, central effective, or narcotic analgesics), or less than three weeks since the discontinuation of these drugs
* Advanced mood disorder
* Radiographic evidence of Grade 2 spondylolisthesis, presence of spinal instability, and advanced degenerative spondylarthrosis
Task Switching Behavior Between Target Templates During Visual Search in Healthy Adults

In this line of research, the researchers having participants engage in task switching between tasks which require a positive (target) template, negative (distractor) template, or neutral (non-informative) template to the cognitive control factors associated with each template type during visual search. This is a basic science study.

The researchers will have participants engage in task switching between tasks which require a positive (target) template, negative (distractor) template, or neutral (non-informative) template to the cognitive control factors associated with each template type during visual search. Looking for impacts of task switching helps to identify the components of the cognitive control system that overlap between different types of attentional templates. This is a basic science study.

Eligibility Criteria:
Inclusion Criteria:

* normal or corrected to normal visual acuity, normal color vision

Exclusion Criteria:

-